India Waives Local Clinical Trials for Certain Foreign-Approved Drugs

The Indian government has waived the local clinical trial requirement for certain drugs approved in the US, UK, Japan, Australia, Canada, and the EU. This waiver applies to orphan drugs, gene therapies, and medicines for rare diseases and pandemics. The move aims to expedite the availability of advanced medications in India.

The Indian government has lifted the requirement for local clinical trials for certain categories of drugs that are already approved in countries like the US, the UK, Japan, Australia, Canada, and the EU.

This waiver affects orphan drugs for rare diseases, gene and cellular therapies, pandemic-specific medications, and new treatments offering significant therapeutic advances.

The initiative seeks to make cutting-edge medical treatments available more rapidly, particularly for diseases like cancer, Spinal Muscular Atrophy, and autoimmune conditions, thus shortening the approval timeline in India.

(With inputs from agencies.)